PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
12.55%
Net income growth 10-15% – Solid. Seth Klarman would see it as healthy if margins also remain stable.
-4.31%
Negative yoy D&A growth lowers the drag on net earnings. Benjamin Graham would confirm if it is due to fully depreciated assets or a slower expansion cycle.
-1173.94%
A negative yoy change in deferred tax might cut future liabilities. Benjamin Graham would verify whether real tax payments are simply being recognized sooner.
-7.99%
Negative yoy SBC growth reduces new equity issuance. Benjamin Graham would verify that enough talent investment remains for growth.
214.02%
Working capital above 30% yoy – Very high. Philip Fisher would demand clarity on whether the buildup is strategic or signals inefficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.21%
A negative yoy AP change means the firm is paying down supplier credit. Benjamin Graham would see it as lowering short-term liabilities if revenue is stable.
259.96%
Above 30% yoy – Major jump. Philip Fisher would demand details on these miscellaneous lines to ensure transparency.
1173.94%
Above 30% yoy – Major jump. Philip Fisher would investigate whether this is a recurring or truly one-time distortion.
18.46%
Operating cash flow growth 15-20% – Very strong. Benjamin Graham would verify if cyclical or stable demand drives this improvement.
36.17%
CapEx above 15% yoy – Significant. Philip Fisher would demand strong evidence of high-ROI projects to offset the spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.17%
Above 15% yoy – Heavy. Philip Fisher would require evidence these invests drive future returns and do not hamper free cash flow too much.
No Data
No Data available this quarter, please select a different quarter.
-70.77%
A negative yoy figure could mean fewer or no new shares or even net buybacks. Benjamin Graham would see it as positive unless expansions need capital that internal cash cannot provide.
No Data
No Data available this quarter, please select a different quarter.